| abstract |
The present invention refers to the combined use of antidepressant agents for the treatment of masculine sexual dysfunction, particularly premature ejaculation, considering that the combinations can comprise a Tricyclic Antidepressant (TCA), a Tetracyclic Antidepressant (TeCA), a Selective Serotonin Reuptake Inhibitor (SSRI), and optionally a Serotonin - Norepinefrine Reuptake Inhibitor (SNRI), in pharmaceutical forms offering bioavailability below the conventional doses used for these antidepressant agents, for the treatment of clinical settings of depression. These combinations allow the treatment of premature ejaculation, increasing the Intravaginal Ejaculation Latency Time for a time above 3 minutes, without the occurrence of adverse side effects. |